Back to search results

CONVO Intervention for Latinx Patients with Solid Tumors

This study is testing a program called CONVO (Communicating with Oncology Nurses about Values from the Outset). The CONVO intervention involves oncology nurses discussing your health-related values as part of your routine cancer care. The goal is to adapt this program specifically for Latinx patients. To join, you must be an adult (age 21 or older) receiving medical oncology care for a solid tumor (a tumor that forms a mass, like in breast or lung cancer). The main goal of this study is to successfully translate and adapt the CONVO intervention for Latinx populations, which will be measured over 24 months. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 234 participants. It focuses on adapting a behavioral intervention for a specific population.
What's involved
You would participate in discussions with an oncology nurse about your health-related values as part of your routine cancer care.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, which is the translation and adaptation of the intervention, will be measured at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04942717

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

Recruiting
NAAges 21+InterventionalHealth services
Memorial Sloan Kettering Cancer Center
~234 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:CONVO intervention

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Translation/transcreation of the CONVO intervention
Measured over 24 months

Conditions

Solid Tumor
Solid Tumor, Adult
Solid Tumor, Unspecified, Adult

Explore related trials

Solid Neoplasm

NCT04942717

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Jacobi Medical Center

    The Bronx, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New Yorkstudy coordinator listed

    Recruiting

  • MSK at Ralph Lauren (All Protocol Activities)

    New York, New Yorkstudy coordinator listed

    Recruiting

  • New York Cancer & Blood Specialists (Data collection only)

    The Bronx, New Yorkstudy coordinator listed

    Recruiting

  • SBH Health System

    The Bronx, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Judith Nelson, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Judith Nelson, MD
[email protected]
646-888-3107
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All participants will be adults (age ≥ 21) providing informed verbal consent. We seek a waiver of signed consent, which will allow use of virtual communication during the COVID-19 pandemic period.
Patients will be eligible as key informants in the translation/transcreation process (Aim 1) if they are receiving medical oncology care for a solid tumor malignancy at RLC, SBH, or Jacobi and speak Spanish as their preferred language. In addition, English-speaking Latinx patients will be eligible to participate in interviews based on the back-translated (Spanish-to-English) version of the Guide
We are focusing on patients with solid tumors rather than hematologic malignancies because 1) patients in the latter group may be receiving initial oncologic treatment in the hospital, whereas our study staff will be based at a distance from the hospital in the ambulatory clinics; 2) the trajectory, patient characteristics, and other aspects of hematologic malignancies tend to be different from solid tumor malignancies such that it would be more difficult to understand the overall impact of the intervention if patients with both types of malignancies w ere included.
Spanish-speaking family/other informal caregivers (collectively referred to as "family") who accompany participating patients to clinic will also be eligible to participate in interviews as part of the Aim 1 translation/transcreation process. These will be individual interviews, conducted separately for patient and family participants.
Clinicians eligible for participation in the transcreation will be oncology physicians, nurses and other key clinical staff (e.g. social workers, advance practice providers, etc.) at RLC and other MSK sites who are Latinx and/or whose practice includes \>20% Latinx patients.
Site leaders at SBH, Jacobi, and RLC with administrative responsibility for medical oncology will be eligible as key informants in transcreation of CONVO.
For the Aim 2 pilot trial, patients will be eligible if they are receiving systemic chemotherapy at SBH or Jacobi for a solid tumor; identify as Latinx; and speak English and/or Spanish. Family and/or informal caregivers who accompany the patient and speak English and/or Spanish will also be eligible (if the patient opts to include the family and/or informal caregiver in the CONVO discussion).
Nurses providing outpatient oncology care in chemotherapy areas at SBH or Jacobi will be eligible to participate in the pilot trial.

Exclusion

Inability to understand consent procedure in either English or Spanish will be an exclusion. (The consenting professional will be bilingual \[English/Spanish\] and able to explain and obtain consent in either language.)

What this trial measures

  • Translation/transcreation of the CONVO intervention24 months

    To translate/transcreate (linguistic plus cultural adaptation) our intervention for implementation with Spanish-speaking Latinx cancer patients receiving outpatient oncologic care in their communities: Comunicar Nuestros Valores a las enfermeras de Oncología desde el comienzo del tratamiento de cáncer.